Healthpeak Properties' Lab Segment Decline Could Finally Show Signs of Bottoming Out

Healthpeak Properties (NYSE: DOC) reports first-quarter 2026 earnings after market close on May 5, with investors focused on whether the healthcare REIT can stabilize fundamentals after a year of declining estimates and technical weakness. The consensus expects $0.43 per share, down 6.5% year-over-year, as the company navigates a challenging environment for senior housing and life science properties. With analyst sentiment deteriorating and the stock trading below most key moving averages, this report will test whether DOC can halt its negative momentum or faces further downside.

Part 1: Earnings Preview

Healthpeak Properties is a healthcare-focused real estate investment trust (REIT) that owns and operates senior housing, life science, and outpatient medical properties across the United States. The company provides essential real estate infrastructure to healthcare providers and life science tenants, making it a key player in the healthcare property sector.

DOC is scheduled to report Q1 2026 earnings after the close on May 5, 2026. Analysts expect earnings of $0.43 per share on revenue estimates that are not uniformly available across sources. The company most recently reported $0.47 per share for Q4 2025, beating estimates by $0.02. Comparing to the same quarter last year, the $0.43 consensus represents a 6.5% decline from the $0.46 reported in Q1 2025, reflecting ongoing headwinds in the business.

Three key themes define this earnings story:

Senior Housing Occupancy and Pricing Power: Investors will scrutinize whether DOC's senior housing portfolio can maintain occupancy gains and pricing momentum amid increased competition and labor cost pressures. This segment has been volatile, and any signs of weakening demand or margin compression could weigh on the stock.

Life Science Portfolio Performance: The life science real estate market has faced significant headwinds from reduced venture capital funding and tenant consolidation. DOC's exposure to this sector makes performance updates critical, particularly around leasing activity, tenant retention, and any potential write-downs or vacancy increases.

Full-Year Guidance and Capital Allocation: With estimates declining throughout 2025 and into 2026, management's commentary on full-year FFO guidance and capital deployment strategy will be closely watched. Investors want clarity on whether the company will pursue acquisitions, dispositions, or increased shareholder returns through dividends or buybacks.

Analyst commentary ahead of the release has been cautious. Recent downgrades from Argus Research and Jefferies reflect concerns about the company's ability to grow earnings in the current environment. Goldman Sachs initiated coverage in January 2026, but the overall sentiment trend has deteriorated over the past month, with one analyst lowering their rating. The consensus remains that DOC faces structural challenges in both senior housing operations and life science leasing that may take several quarters to resolve.

Part 2: Historical Earnings Performance

Healthpeak Properties has demonstrated a pattern of modest earnings performance over the past four quarters, with two beats, two in-line results, and no outright misses. The company reported $0.46 in Q1 2025 (matching estimates), $0.46 in Q2 2025 (in line), $0.46 in Q3 2025 (beating by 2.22%), and $0.47 in Q4 2025 (beating by 4.44%).

The trend shows improving execution in the second half of 2025, with DOC delivering back-to-back beats after two flat quarters. The magnitude of surprises has been relatively small—ranging from in-line to a 4.44% beat—suggesting the company is managing expectations conservatively but not dramatically outperforming. The consistency of results around the $0.46-$0.47 range indicates stable but unspectacular operational performance.

Looking ahead to Q1 2026, the $0.43 consensus represents a notable step down from the $0.46-$0.47 range of recent quarters, reflecting analyst concerns about deteriorating fundamentals. Whether DOC can deliver another modest beat or faces its first miss in over a year will be a key test of management's credibility and the company's operational resilience.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Healthpeak Properties typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around DOC earnings shows moderate volatility, with an average absolute Day 0 move of 0.84% and Day +1 move of 3.57%. The Day +1 reaction is notably larger, consistent with after-hours reporting where the full market response occurs the following session.

The most recent earnings on February 2, 2026, saw a muted Day 0 decline of 1.86%, followed by a 2.78% drop on Day +1 despite beating estimates—suggesting investors were disappointed by guidance or underlying trends. Prior quarters showed mixed reactions: July 2025 delivered a strong 5.49% Day +1 gain, while April 2025 saw a sharp 5.21% Day +1 decline despite meeting estimates.

The average Day +1 range of 4.40% indicates significant intraday volatility following earnings, with moves occasionally exceeding 6%. Investors should prepare for potential swings of 3-4% in either direction based on not just the EPS result, but management's commentary on occupancy trends, leasing activity, and forward guidance.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.10% (±$1.16) for the May 15 expiration, significantly higher than DOC's average historical Day +1 move of 3.57%. This elevated implied volatility of 44.53% suggests options traders are anticipating a larger-than-typical reaction to this earnings report, possibly reflecting heightened uncertainty around guidance and sector headwinds.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Healthpeak Properties, with a consensus rating of 3.84 out of 5.0 (between Hold and Buy) and an average price target of $19.22. The current breakdown shows 7 Strong Buys, 2 Moderate Buys, and 10 Holds, with no sell ratings. This implies 18% upside from the current price of $16.29, though the wide range of targets—from a low of $16.00 to a high of $29.00—reflects significant disagreement about the company's prospects.

Sentiment has deteriorated over the past month, with one analyst downgrading their rating while the Hold camp expanded from 9 to 10. The average recommendation slipped from 3.89 to 3.84, indicating growing caution. Recent downgrades from Argus Research (February 5) and Jefferies (December 16, 2025) highlight concerns about near-term headwinds, while Goldman Sachs' January 9 initiation provided a fresh bullish perspective.

The $19.22 consensus target suggests analysts believe DOC is undervalued at current levels, but the deteriorating sentiment trend and clustering of Hold ratings indicate most are taking a wait-and-see approach. The 18% implied upside is meaningful, but investors should note that 10 of 19 analysts rate the stock a Hold, reflecting uncertainty about the timing and magnitude of any recovery.

Part 4: Technical Picture

Healthpeak Properties enters earnings with a bearish technical setup. The Barchart Technical Opinion stands at 88% Sell, unchanged from both one week and one month ago, indicating persistent negative momentum with no recent improvement.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates near-term momentum is decisively negative, with all short-term indicators pointing lower
• Medium-term (50% Sell): Moderate sell signal suggests intermediate-term weakness, though less extreme than the short-term picture
• Long-term (100% Sell): Strong sell signal reflects entrenched weakness in the longer-term trend, with no signs of reversal

Trend Characteristics: The combination of Average strength and Average direction suggests DOC is in a steady downtrend without extreme volatility—a grinding decline rather than a sharp collapse, which may continue absent a strong catalyst from earnings.

At $16.29, DOC trades above its 5-day ($16.18) and 10-day ($16.28) moving averages, indicating a minor short-term bounce, but remains below all longer-term averages: 20-day ($16.60), 50-day ($16.92), 100-day ($16.87), and 200-day ($17.42). This configuration—short-term support but longer-term resistance overhead—suggests any rally faces multiple technical hurdles. The 200-day moving average at $17.42 represents a key resistance level nearly 7% above current prices. With the stock in a confirmed downtrend across all major timeframes and the options market pricing a 7% move, the technical setup is cautionary heading into earnings. DOC would need a significant positive surprise and strong guidance to break through overhead resistance and reverse the prevailing bearish momentum.